BIND Therapeutics, Inc. ( BIND ) saw a big move last session, as the company's shares fell by over 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for BIND, as the stock is now up over 38% in the past one-month time frame.
Although this slump was obviously disappointing, the current year earnings consensus has moved higher over the past few weeks for this clinical-stage nanomedicine platform company. This suggests that the recent slump might be a temporary blip on the radar for BIND. So make sure to keep an eye on this stock going forward to see if last day's price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.
BIND currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same sector include Biogen Idec Inc. ( BIIB ), The Medicines Company ( MDCO ) and Osiris Therapeutics, Inc. ( OSIR ). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBIND THERAPEUTC (BIND): Free Stock Analysis ReportBIOGEN IDEC INC (BIIB): Free Stock Analysis ReportMEDICINES CO (MDCO): Free Stock Analysis ReportOSIRIS THERAPTC (OSIR): Free Stock Analysis ReportTo read this article on Zacks.com click here.